The Chong Kun Dang’s extremely obese treatment has been confirmed effectiveness through clinical trials in the U.S.

Published: 2015-01-12 14:06:28

Updated: 2015-01-12 14:29:54

Chong Kun Dang (CEO Jung-woo Kim)confirmed effectiveness of the extremely obese treatment ‘CKD-732’, which has recently got on a Phase 3 clinical trialfor the Prader-Willi Syndrome, on a new obese disorder.

Zafgen, having joint research and development of CKD-732 (generic name: beloranib) with Chong Kun Dang, announced the result of the Clinical Study Phase 2a on a hypothalamic damage obese di...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.